Biodistribution and Dosimetry Evaluation of [124I]FIAU
Status: | Completed |
---|---|
Conditions: | Orthopedic |
Therapuetic Areas: | Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 5/27/2013 |
Start Date: | December 2010 |
End Date: | March 2013 |
Contact: | Martin R Feeney, B.Sc. |
Email: | martin.feeney@covance.com |
Phone: | 1-250-348-1020 |
Biodistribution and Dosimetry of [124i]FIAU in Patients With Prosthetic Joint Infection of The Knee or Hip and Healthy Subjects Using PET-CT Scanning
This protocol will evaluate the biodistribution and dosimetry of [124I]FIAU in both healthy
volunteers and patients with prosthetic joint infections. This pilot study will also
investigate the safety and tolerability of [124I]FIAU.
The following are the main inclusion criteria for all subjects:
1. Males or females age > 18 years
2. Informed consent
3. Subjects with chronic medical conditions such as hypertension and diabetes should be
considered stable by the principal investigator
4. Women should be postmenopausal or surgically sterile
5. Able to return for all study assessments
In addition, the following main inclusion criteria apply for subjects with suspected
prosthetic joint infection:
1. Operative intervention planned in the 30 days following study enrollment
2. Prosthetic joint implant in site for more than 3 months prior to enrollment
The following are the main exclusion criteria for all subjects:
1. Unable to comply with study requirements
2. Indication in the opinion of the principal investigator for surgery within 48 hours
of presentation.
3. Receipt of any antibiotic therapy in the 2 weeks preceding imaging
4. Immunosuppression, e.g., human immunodeficiency virus (HIV) infection, s/p organ
transplantation, receipt of steroids for > 10 days at > 10 mg of prednisone
equivalent daily within the 90 days prior to enrollment
5. Requirement for any medication that predisposes to lactic acidosis (e.g., metformin,
iron, isoniazid and salicylates; see Appendix A)
6. Requirement for any medication that has potential mitochondrial toxicity, e.g.,
nucleoside analogues (zidovudine, didanosine, stavudine)
7. History of an inherited mitochondrial disorder (e.g., Leber's hereditary neuropathy,
neuropathy, ataxia, retinitis pigmentosa and ptosis [NARP], myoneurogenic
gastrointestinal encephalopathy [MNGIE], myoclonic epilepsy with ragged red fibers
[MERFF] and mitochondrial myopathy, encephalomyopathy, lactic acidosis and
stroke-like syndrome [MELAS]
8. Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
9. Pre-existing myopathy or neuropathy
10. Abnormal liver function tests defined as alanine aminotransferase (ALT) > the upper
limit of normal (ULN), aspartate aminotransferase (AST) > ULN, gamma glutamyl
transferase (GGT) > ULN
11. Alcohol use > 3 units per day in men or 2 units per day in women or active
intravenous drug use
12. Creatinine clearance < 30 mL/min
13. Body mass index > 40
14. Life expectancy < 6 months
15. Hypersensitivity to iodine
We found this trial at
4
sites
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials